

2015
Press release



www.genfit.com

GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON FEBRUARY 24, 2015

Lille (France), Boston (Massachusetts, United States), January 19th, 2015 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, , today announces that it will hold a Combined General Shareholders' Meeting ("the Shareholders' Meeting") on February 24, 2015, at 10:30am, in the Faculty of Pharmaceutical & Biological Sciences of Lille premises, located Parc Eurasanté, 3 rue du Professeur Laguesse, F-59000 Lille.

The Notice of Meeting of this Shareholders' Meeting was published this day, in the French official legal bulletin ("BALO"). It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this Meeting. It is also available on the Company's website, in the investors' room (<http://www.genfit.com/investors/documentation-center/>).

All documentation regarding this Shareholders' Meeting will be made available to shareholders in accordance with existing regulations and will be available on the Company's website on February 3rd, 2015, at the latest.

Precision regarding the Shareholders' Meeting:

Only shareholders having registered their shares at least two business days prior to the date of the Shareholders' Meeting, by midnight Paris time, will be able to attend.

Shareholders holding "au porteur" (bearer) shares will need to obtain an "attestation de participation" (certificate of shareholding) from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by mail, or to the admission card request.

Written questions from shareholders must be received until four business days prior to the Shareholders' Meeting at the latest by registered letter, addressed to the registered office.

Shareholders may obtain, in preparation of the Shareholders' Meeting, the documents referred to in articles R.225-81 and R.225-83 of the French Commercial Code, within the periods and in conditions set out in article R.225-88 of the same Code, by sending a simple request by regular mail to the Company's registered office (GENFIT / Finance Department, Parc Eurasanté, 885 Avenue Eugène Avinée, 59120 Loos).

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

Contacts

GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

MILESTONES – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr